d-LSD-induced c-Fos expression occurs in a population of oligodendrocytes in rat prefrontal cortex

European Journal of Pharmacology

Volumn 583, Issue 1, 2008, Pages 40-47

  Reissig, Chad J ^a   Rabin, Richard A ^a   Winter, Jerrold C ^a   Dlugos, Cynthia A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

c Fos; d LSD; Immunocytochemistry; Neurons; Oligodendrocytes; Prefrontal cortex

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; LYSERGIDE; MESSENGER RNA; NEURON SPECIFIC ENOLASE; NEURON SPECIFIC NUCLEAR PROTEIN; PROTEIN ANTIBODY; PROTEIN C FOS;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN REGION; CELL LABELING; CELL NUCLEUS; CELL SIZE; CELL SPECIFICITY; CELL SUBPOPULATION; CELL TYPE; CONTROLLED STUDY; GENE INDUCTION; IMMEDIATE EARLY GENE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; NEUROFILAMENT; NONHUMAN; OLIGODENDROGLIA; ONCOGENE C FOS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PYRAMIDAL NERVE CELL; RAT; STIMULUS RESPONSE;

ANIMALS; ASTROCYTES; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GENES, FOS; GLIAL FIBRILLARY ACIDIC PROTEIN; HALLUCINOGENS; IMMUNOHISTOCHEMISTRY; LYSERGIC ACID DIETHYLAMIDE; MALE; MICROGLIA; MICROSCOPY, CONFOCAL; OLIGODENDROGLIA; PERFUSION; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; RATS, INBRED F344;

EID: 39649102936     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.12.031     Document Type: Article

References (67)

1. 2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 20 (1999) 92-96
2. Abraham H.D., Aldridge A.M., and Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology 14 (1996) 285-298
3. Butt A.M. Neurotransmitter-mediated calcium signalling in oligodendrocyte physiology and pathology. GLIA 54 (2006) 666-676
4. Ceccatelli S., Villar M.J., Goldstein M., and Hokfelt T. Expression of c-Fos immunoreactivity in transmitter-characterized neurons after stress. Proc. Natl. Acad. Sci. USA 86 (1989) 9569-9573
5. Chaudhuri A., Zangenehpour S., Rahbar-Dehgan F., and Ye F. Molecular maps of neural activity and quiescence. Acta Neurobiol. Exp. 60 (2000) 403-410
6. Christensen J., Holcomb J., and Garver D.L. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res. 130 (2004) 71-78
7. Cohen R.I., Molina-Holgado E., and Almazan G. Carbachol stimulates c-fos expression and proliferation in oligodendrocyte progenitors. Mol. Brain Res. 43 (1996) 193-201
8. Conn P.J., and Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharmacol. Toxicol. 37 (1997) 205-237
9. Cornea-Hébert V., Riad M., Wu C., Singh S.K., and Descarries L. Cellular and subcellular distribution of serotonin 5-HT2A receptor in the central nervous system of the adult rat. J. Comp. Neurol. 409 (1999) 187-209
10. de Medeiros M.A., CarlosReis L., and Eugenio Mello L. Stress-induced c-Fos expression is differentially modulated by dexamethasone, diazepam and imipramine. Neuropsychopharmacology 30 (2005) 1246-1256
11. Dayer A.G., Cleaver K.M., Abouantoun T., and Cameron H.A. New GABAergic interneurons in the adult neocortex and striatum are generated from different precursors. J. Cell Biol. 168 (2005) 415-427
12. Dlugos C.A., and Pentney R.J. Quantitative immunocytochemistry of GABA and synaptophysin in the cerebellar cortex of old ethanol-fed rats. Alcohol Clin. Exp. Res. 26 (2002) 1728-1733
13. Eckler J.R., Chang-Fong J., Rabin R.A., Smith C., Teitler M., Glennon R.A., and Winter J.C. Behavioral characterization of 2-O-desmethyl and 5-O-desmethyl metabolites of the phenylethylamine hallucinogen DOM. Pharmacol. Biochem. Behav. 75 (2003) 845-852
14. Fiorella D., Rabin R.A., and Winter J.C. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: antagonist correlation analysis. Psychopharmacology 121 (1995) 347-356
15. Frankel P.S., and Cunningham K.A. The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Res. 958 (2002) 251-260
16. Gabbott P.L.A., and Bacon S.J. Local circuit neurons in the medial prefrontal cortex (areas 24a,b,c, 25 and 32) in the monkey: 1. Cell morphology and morphometrics. J. Comp. Neurol. 364 (1996) 567-608
17. Glennon R.A., Titeler M., and McKenney J.D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35 (1984) 2505-2511
18. Glennon R.A., Young R., Jacyno J.M., Slusher M., and Rosecrans J.A. DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur. J. Pharmacol. 86 (1983) 450-459
19. Gresch P.J., Barrett R.J., Sanders-Bush E., and Smith R.L. 5-Hydroxytrypatamine (serotonin)2A receptors in rat anterior cingulate cortex mediate the discriminative stimulus properties of d-lysergic acid diethylamide. J. Pharmacol. Exp. Ther. 320 (2007) 662-669
20. Gresch P.J., Strickland L.V., and Sanders-Bush E. Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Neuroscience 114 (2002) 707-713
21. Gundersen H.J.G. Notes on the estimation of the numerical density of arbitrary profile. The edge effect. J. Microsc. 111 (1977) 219-222
22. Guzowski J.F. Insights into immediate-early gene function in hippocampal memory consolidation using antisense oligonucleotide and fluorescent imaging approaches. Hippocampus 12 (2002) 86-104
23. Guzowski J.F., Timlin J.A., Roysam B., McNaughton B.L., Worley P.F., and Barnes C.A. Mapping behaviorally relevant neural circuits with immediate-early gene expression. Cur. Opin. Neurobiol. 15 (2005) 599-606
24. Halpern J.H., and Pope H.G. Hallucinogen persisting perception disorder: what do we know after 50 years?. Drug Alcohol Depend. 69 (2003) 109-119
25. Herkenham M., Lee H.Y., and Baker R.A. Temporal and spatial patterns of c-fos mRNA induced by intravenous interleukin-1: a cascade of non-neuronal cellular activation at the blood-brain barrier. J. Comp. Neurol. 400 (1998) 175-196
26. Hof P.R., and Nimchinsky E.A. Regional distribution of neurofilament and calcium-binding proteins in the cingulate cortex of the macaque monkey. Cerebral Cortex 2 (1992) 356-367
27. Hofmann A. Psychotomimetic drugs; chemical and pharmacological aspects. Acta Physiol. Pharmacol. Neerl. 8 (1959) 240-258
28. Jakab R.L., and Goldman-Rakic P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 735-740
29. Jansson A., Tinner B., Bancila M., Verge D., Steinbusch H.W.M., Agnati L.F., and Fuxe K. Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain. J. Chem. Neuroanat. 22 (2001) 185-203
30. Kovács K.J. c-Fos as a transcription factor: a stressful (re)view from a functional map. Neurochem. Int. 33 (1998) 287-297
31. Lewis D.A. Structure of the human prefrontal cortex. Am. J. Psychiatry 161 (2004) 1366
32. López-Giménez J.F., Mengod G., Palacios J.M., and Vilaro M.T. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn Schmiederg's Arch. Pharmacol. 356 (1997) 446-454
33. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., and Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117 (2003) 697-706
34. Lu Q.R., Park J.K., Noll E., Chan J.A., Alberta J., Yuk D., Alzmora G., Louis D.N., Stiles C.D., Rowitch D.H., and Black P.M. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10851-10856
35. Maćkowiak M., Chocyk A., Fijal K., Czyrak A., and Wedzony K. c-Fos proteins, induced by the serotonin receptor agonist DOI, are not expressed in 5-HT2A positive cortical neurons. Mol. Brain Res. 71 (1999) 358-363
36. Matute C. Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends Molec. Med. 12 (2006) 289-292
37. Miller E.K. The prefrontal cortex and cognitive control. Nature Rev. Neurosci. 1 (2000) 59-65
38. Mogensen J., and Holm S. The prefrontal cortex and variants of sequential behaviour indications of functional differentiation between subdivisions of the rat's prefrontal cortex. Behav. Brain Res. 63 (1994) 89-100
39. Morgan J.I., and Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Ann. Rev. Neurosci. 14 (1991) 421-451
40. Mullen R.J., Buck C.R., and Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 116 (1992) 201-211
41. Muschamp J.W., Regina M.J., Hull E.M., Winter J.C., and Rabin R.A. Lysergic acid diethylamide and [-]-2,5-dimehoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex. Brain Res. 1023 (2004) 134-140
42. Nichols C.D., Garcia E.E., and Sanders-Bush E. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Mol. Brain. Res. 111 (2003) 182-188
43. Nichols D.E. Hallucinogens. Pharmacol. Ther. 101 (2004) 131-181
44. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. (1986), Academic Press
45. Pazos A., Cortes R., and Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II serotonin-2 receptors. Brain Res. 346 (1985) 231-249
46. Pyykönen I., and Koistinaho J. c-fos protein like immunoreactivity in non-neuronal cells of rat peripheral nerve after transection. Acta Neuropathol. 82 (1991) 66-71
47. Richter-Landsberg C., and Vollgraf U. Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells. Exp. Cell Res. 244 (1998) 218-229
48. Sánchez-Abarca L.J., Tabernero A., and Medina J.M. Oligodendrocytes use lactate as a source of energy and as a precursor of lipids. GLIA 36 (2001) 321-329
49. Santana N., Bortolozzi A., Serrats J., Mengod G., and Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons in the rat prefrontal cortex. Cerebral Cortex 14 (2004) 1100-1109
50. Schreiber R., Brocco M., and Millan M.J. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur. J. Pharmacol. 264 (1994) 99-102
51. Scruggs J.L., Patel S., Bubser M., and Deutch A.Y. DOI-induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons. J. Neurosci. 20 (2000) 8846-8852
52. Shetty A.K., and Turner D.A. Non-phosphorylated neurofilament protein immunoreactivity in adult and developing rat hippocampus: specificity and application in grafting studies. Brain Res. 10 (1995) 293-306
53. Simpson C.S., and Morris B.J. Basic fibroblast growth factor induces c-fos expression in primary cultures of rat striatum. Neurosci. Lett. 170 (1994) 281-285
54. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., Starkey M., Webster M.J., Yolken R.H., and Bahn S. Oligodendroctye dysfunction in schizophrenia and bipolar disorder. Lancet 362 (2003) 798-805
55. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., and Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 67 (2004) 269-275
56. Uylings H.B., and van Eden C.G. Qualitative and quantitative comparison of the prefrontal cortex in rat and in primates, including humans. Prog. Brain Res. 85 (1990) 31-62
57. Uylings H.B.M., Groenewegen H.J., and Kolb B. Do rats have a prefrontal cortex? Behav. Brain Res. 146 (2003) 3-17
58. Van Eden C.G., and Uylings H.B. Cytoarchitectonic development of the prefrontal cortex in the rat. J. Comp. Neurol. 241 (1985) 253-267
59. Vollenweider F.Z., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., and Angst J. Positron emission tomography an dfluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16 (1997) 357-372
60. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F.I., Bäbler A., Vogel H., and Hell D. Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. NeuroReport 9 (1998) 3897-3902
61. West M.J. New stereological methods for counting neurons. Neurobiol. Aging 14 (1993) 275-285
62. Willins D.L., Deutch A.Y., and Roth B.L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27 (1997) 79-82
63. Winter J.C. Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine. J. Pharamcol. Exp. Ther. 204 (1978) 416-423
64. Winter J.C., Eckler J.R., and Rabin R.A. Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with D-LSD and PCP as discriminative stimuli. Psychopharmacology (Berl) 172 (2004) 233-240
65. Wolf H.K., Buslei R., Schmidt-Kastner R., Schmidt-Kastner P.K., Pietsch T., Wiestler O.D., and Blümcke I. NeuN A useful neuronal marker of diagnostic histopathology. J. Histochem. Cytochem. 44 (1996) 1167-1171
66. Wolswijk G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain 123 (2000) 105-115
67. Zhai Y., George C.A., Zhai J., Nisenbaum E.S., Johnson M.P., and Nisenbaum L.K. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28 (2003) 45-52